ICAD icad Inc.

iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on November 10, 2022.

Conference Call
Thursday, November 10, 2022 at 4:30 PM ET
Domestic: 888-506-0062
International: 973-528-0011
Conference ID: 393244
Webcast: 
   

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit .

Media Inquiries:

Jessica Burns, iCAD



Investor Inquiries:

iCAD Investor Relations



EN
27/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on icad Inc.

 PRESS RELEASE

iCAD Reports Financial Results for First Quarter Ended March 31, 2025

iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin o...

 PRESS RELEASE

iCAD Collaborates with Microsoft to provide access to its Mammography ...

iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN) iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Sui...

 PRESS RELEASE

iCAD Expands Executive Leadership with Appointment of Mark Koeniguer a...

iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringi...

 PRESS RELEASE

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ende...

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenue...

 PRESS RELEASE

iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on ...

iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: About iCAD, Inc. iCAD, Inc....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch